IP Library Granted Patent US 9,173,947
Granted Patent B2
US 9,173,947 · App. 14/335,719 · Granted Nov 3, 2015

Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,173,947
App. No.
14/335,719
Granted
Nov 3, 2015
Kind
B2
Abstract

The present invention provides, among other things, polymeric reagents suitable for reaction with biologically active agents to form conjugates, the polymeric reagents comprising one or more polymer chains and a plurality of hydroxyapatite-targeting moieties, and optionally the reagents include one or more degradable linkages that serve to divide the polymer chains into polymer segments having a molecular weight suitable for renal clearance.

Claims (12)

1. A heterobifunctional, substantially linear, hydroxyapatite-targeting polymer having the structure:

Z—(X 1 ) a -L 1 -(X 2 ) b -[POLY 1 -(X 3 ) c -L 2 -(X 4 ) d ] m -POLY 2 -(X 5 ) e —Y

wherein:

each POLY 1 and POLY 2 , which may be the same or different, is a water-soluble, non-peptidic polymer having a number average molecular weight of less than 8,000 Da;

each X 1 , X 2 , X 3 , X 4 , and X 5 , which may be the same or different, is a spacer moiety;

L 1 is a linkage;

each L 2 is a hydrolytically or enzymatically cleavable linkage selected from the group consisting of carbamate and amide;

Z is a hydroxyapatite-targeting moiety;

Y is a functional group;

each a, b, c, d, and e, which may be the same or different, is either zero or one; and

m is an integer in the range of 1-10.

2. The polymer of claim 1 , wherein each of X 1 , X 2 , X 3 , X 4 , and X 5 , when present, is selected from the group consisting of —C(O)O—, —OC(O)—, —CH 2 —C(O)O—, —CH 2 —OC(O)—, —C(O)O—CH 2 —, —OC(O)—CH 2 —, —C(O)—, —C(O)—NH—, —NH—C(O)—NH—, —O—C(O)—NH—, —C(S)—, —CH 2 —, —CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 —CH 2 —, —CH 2 —O—, —O—CH 2 —CH 2 —, —CH 2 —O—CH 2 —, —CH 2 —CH 2 —O—, —O—CH 2 —CH 2 —CH 2 —, —CH 2 —O—CH 2 —CH 2 —, —CH 2 —CH 2 —O—CH 2 —, —CH 2 —CH 2 —CH 2 —O—, —O—CH 2 —CH 2 —CH 2 —CH 2 —, —CH 2 —O—CH 2 —CH 2 —CH 2 —, —CH 2 —CH 2 —O—CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 —O—CH 2 —, —CH 2 —CH 2 —CH 2 —CH 2 —O—, —C(O)—NH—CH 2 —, —C(O)—NH—CH 2 —CH 2 —, —CH 2 —C(O)—NH—CH 2 —, —CH 2 —CH 2 —C(O)—NH—, —C(O)—NH—CH 2 —CH 2 —CH 2 —, —CH 2 —C(O)—NH—CH 2 —CH 2 —, —CH 2 —CH 2 —C(O)—NH—CH 2 —, —CH 2 —CH 2 —CH 2 —C(O)—NH—, —C(O)—NH—CH 2 —CH 2 —CH 2 —CH 2 —, —CH 2 —C(O)—NH—CH 2 —CH 2 —CH 2 —, —CH 2 —CH 2 —C(O)—NH—CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 —C(O)—NH—CH 2 —, —CH 2 —CH 2 —CH 2 —C(O)—NH—CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 —CH 2 —C(O)—NH—, —C(O)—O—CH 2 —, —CH 2 —C(O)—O—CH 2 —, —CH 2 —CH 2 —C(O)—O—CH 2 —, —C(O)—O—CH 2 —CH 2 —, —NH—C(O)—CH 2 —, —CH 2 —NH—C(O)—CH 2 —, —CH 2 —CH 2 —NH—C(O)—CH 2 —, —NH—C(O)—CH 2 —CH 2 —, —CH 2 —NH—C(O)—CH 2 —CH 2 —, —CH 2 —CH 2 —NH—C(O)—CH 2 —CH 2 —, —C(O)—NH—CH 2 —, —C(O)—NH—CH 2 —CH 2 —, —O—C(O)—NH—CH 2 —, C(O)—NH—CH 2 —CH 2 —, —NH—CH 2 —, —NH—CH 2 —CH 2 —, —CH 2 —NH—CH 2 —, —CH 2 —CH 2 —NH—CH 2 —, —C(O)—CH 2 —, —C(O)—CH 2 —CH 2 —, —CH 2 —C(O)—CH 2 —, —CH 2 —CH 2 —C(O)—CH 2 —, —CH 2 —CH 2 —C(O)—CH 2 —CH 2 —, —CH 2 —CH 2 —C(O)—, —CH 2 —CH 2 —CH 2 —C(O)—NH—CH 2 —CH 2 —NH—, —CH 2 —CH 2 —CH 2 —C(O)—NH—CH 2 —CH 2 —NH—C(O)—, —CH 2 —CH 2 —CH 2 —C(O)—NH—CH 2 —CH 2 —NH—C(O)—CH 2 —, —CH 2 —CH 2 —CH 2 —C(O)—NH—CH 2 —CH 2 —NH—C(O)—CH 2 —CH 2 —, —C(O)—NH—(CH 2 ) 1-6 —NH—C(O)—, —NH—C(O)—NH—(CH 2 ) 1-6 —NH—C(O)—, and —O—C(O)—NH—(CH 2 ) 1-6 —NH—C(O)—, —O—C(O)—NH—[CH 2 ] h —(OCH 2 CH 2 ) j —, —NH—C(O)—O—[CH 2 ] h —(OCH 2 CH 2 ) j —, bivalent cycloalkyl group, —O—, —S—, —N(R 6 )—, and combinations thereof, wherein R 6 is H or an organic radical selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl and substituted aryl, (h) is zero to six, and (j) is zero to 20.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL 33760, FRAME 0791 Recorded Oct 14, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 036865/0265 →
GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Oct 6, 2015
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 036796/0562 →
SECURITY INTEREST Recorded Sep 17, 2014
From: NEKTAR THERAPEUTICS
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 033760/0791 →